Global regulatory bodies, including the FDA and EMA, have introduced a legal obligation for drug manufacturers to implement mitigation strategies that aim to minimize the risk of nitrosamine formation in drug products.
The addition of antioxidants to drug formulations is a safe and viable, FDA-recommended mitigation strategy for inhibition of nitrosamine formation in drug products. Prevention of formation of potentially carcinogenic impurities is possible with commonly used ascorbic acid and alpha-tocopherol.
When added to your formulation as excipients, ascorbic acid and alpha-tocopherol bring multiple benefits, including:
Overcoming critical formulation challenges takes more than adding ingredients – it takes a reliable partner. Whether it’s supporting you with the reformulation of your existing drug product, or helping to bring new innovative therapies to market, we can assist you in implementing a proven mitigation strategy to reduce the risk of nitrosamine formation in your pharmaceuticals.
DSM has more than 70 years of experience in producing and securing the supply of vitamin APIs and excipients. Manufactured in GMP-certified facilities, our pharmaceutical grade ascorbic acid and alpha-tocopherol excipients are ingredients you can trust.
We have the scientific know-how and cutting-edge technology you need to mitigate the risk of nitrosamines in your oral solid, semisolid, liquid or injectable formulations.
Our excipient production is governed by a wide range of global certification systems to support the success of your pharmaceutical solutions, including GMP, CEPs, DMFs and compliance with multiple pharmacopeia.
DSM is global company with a global footprint and strong local knowledge.
